| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514725000 | Vitamin A compound or derivative | 13 |
| 20080227868 | Composition Comprising an Hdac Inhibitor in Combination with a Retinoid - The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular useful for treating wrinkles but also for thickening the epidermis and for improving hair growth. | 09-18-2008 |
| 20080255244 | CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells - A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described. | 10-16-2008 |
| 20080275133 | Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation - The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided. | 11-06-2008 |
| 20080275134 | Methods for Treatment of Retinal Degenerative Disease - A method is provided for treating a degenerative disease in a vertebrate eye. A method is further provided for preventing photoreceptor degeneration in a vertebrate eye. | 11-06-2008 |
| 20090054532 | Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation - Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies. | 02-26-2009 |
| 20090131537 | Wound healing compositions - Formulations and methods for treating wounds utilizing these formulations are disclosed. The formulations accelerate wound healing by providing a unique serum-free cellular nutrient medium that supports wound healing of mammalian skin in the absence of protein growth factors. The protein-free composition contains physiological levels of a retinoid compound. This retinoid-containing composition enhances epidermal wound healing of both normal acute and chronic wounds by stimulating the growth of the adult epidermal keratinocytes without the need of any protein growth factors. The wound healing active composition may be used in combination with a topical wound gel preparation including both proteinaceous and non-proteinaceous biopolymers and hydrogels. | 05-21-2009 |
| 20100063162 | METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST - A method for predicting preventive and/or therapeutic effect of an RAR-α agonist on a malignant tumor, which comprises the steps of measuring an expression level of a class of p160 family molecule and an expression level of a class of SP110 family molecule in a sample collected from the malignant tumor of a patient, and when the class of the p160 family molecule is dominant in a balance between the expression level of the class of the p160 family molecule and the expression level of the class of the SP110 family molecule, determining that an RAR-α agonist is effective for therapeutic treatment of the malignant tumor of the patient. | 03-11-2010 |
| 20100113610 | METHODS FOR CONTROLLING INFLAMMATORY AND IMMUNOLOGICAL DISEASES - The present invention provides methods for generating mucosal tissue homing immunosuppressive T-cells comprising treating naïve T-cells with retinoids and/or retinoid agonists. Methods are also provided for treating a mammal having an inflammatory or immunological disease by administering a therapeutically effective dose of retinoids and/or retinoid agonists. Additional methods are also provided for boosting the immune system of a mammal by inhibiting the generation of immunosuppressive T-cells by administering a therapeutically effective dose of a retinoid receptor antagonist to the mammal. | 05-06-2010 |
| 20100267840 | STABILIZERS FOR HYDROPHOBIC COMPONENTS IN PERSONAL CARE COMPOSITIONS - The present invention provides personal care compositions, as well as methods for stabilizing a degradable of reactive hydrophobic, cosmetically acceptable, component in an aqueous composition. | 10-21-2010 |
| 20120108672 | OPHTHALMIC COMPOSITION AND METHOD FOR PREVENTION OF CLOUDINESS/PRECIPITATION - An ophthalmic composition characterized by comprising (A) vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and at least one component selected from (C) trometamol, (D) polyhydric alcohols, (E) a sugar, (F) phosphoric acid and salt thereof and (G) monovalent neutral salts. | 05-03-2012 |
| 20140005274 | AQUEOUS OPHTHALMIC COMPOSITION | 01-02-2014 |
| 20150051296 | USE OF FATTY ACID TO REDUCE SKIN IRRITATION ASSOCIATED WITH RETINOID THERAPY - A composition and a method that is effective to reduce, limit, or diminish one or more side effects of a retinoid are described. The composition includes a retinoid and a free fatty acid. The composition may further include one or more cosmetically suitable ingredients so long as they do not interfere with the efficaciousness of the free fatty acid. The method for reducing, limiting, or diminishing a side effect associated with the topical administration of a retinoid to a skin area of a subject includes topically administering a free fatty acid to the skin area prior to, during, and/or after topical administration of the retinoid. | 02-19-2015 |
| 20160129134 | COMPOSITIONS COMPRISING CROSS-LINKED HYALURONIC ACID AND CYCLODEXTRIN - The present invention relates to a hyaluronic acid composition comprising a hyaluronic acid and one or more cyclodextrin molecules covalently bound to said hyaluronic acid via a bi- or polyfunctional crosslinking agent, wherein the covalent bonds between said hyaluronic acid and said crosslinking agent and between said crosslinking agent and said cyclodextrin molecules are ether bonds. The present invention relates to medical and cosmetic (non-medical) uses of such compositions further comprising a pharmaceutical or medical agent and to a method of preparing a slow release formulation. | 05-12-2016 |
